StockWatch
·
Biotechnology: Pharmaceutical Preparations
SplitOct 2, 2026, 04:17 PM

Enlivex Ltd. Seeks Shareholder Approval for Reverse Stock Split

AI Summary

Enlivex Ltd. is holding an Extraordinary General Meeting on October 16, 2026, to seek shareholder approval for a reverse stock split. The initial proposal involves a reverse split with a ratio between 1-for-13 and 1-for-16, with the Board of Directors authorized to set the final ratio. Additionally, shareholders will vote on authorizing the Board to implement further reverse splits within the next 12 months, with an aggregate ratio ranging from 1-for-2 to 1-for-1,000. The primary objective of these actions is to increase the company's share price to comply with Nasdaq's minimum bid price requirement and avoid delisting, as the stock has been trading below $1.00.

Key Highlights

  • Enlivex Ltd. announces an Extraordinary General Meeting on October 16, 2026, to vote on a reverse stock split.
  • Proposal includes a reverse split ratio between 1-for-13 and 1-for-16, with the Board to determine the final ratio.
  • Shareholders will also vote to authorize the Board to effect additional reverse splits with an aggregate ratio between 1-for-2 and 1-for-1,000 within 12 months.
  • The primary goal is to increase the stock price to meet Nasdaq's minimum bid price requirement of $1.00.
  • The company's shares have closed below $1.00 since September 10, 2026, risking delisting.
  • The Board of Directors unanimously recommends voting FOR the reverse split proposal.